174 related articles for article (PubMed ID: 16926775)
1. Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.
Montaner JS; Schutz M; Schwartz R; Jayaweera DT; Burnside AF; Walmsley S; Saag MS
MedGenMed; 2006 May; 8(2):36. PubMed ID: 16926775
[TBL] [Abstract][Full Text] [Related]
2. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P
J Acquir Immune Defic Syndr; 2002 Apr; 29(5):464-70. PubMed ID: 11981362
[TBL] [Abstract][Full Text] [Related]
3. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
[TBL] [Abstract][Full Text] [Related]
5. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
Cardiello PG; Monhaphol T; Mahanontharit A; van Heeswijk RP; Burger D; Hill A; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P
J Acquir Immune Defic Syndr; 2003 Apr; 32(4):375-9. PubMed ID: 12640194
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
8. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
[TBL] [Abstract][Full Text] [Related]
9. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.
Pai MP; Schriever CA; Diaz-Linares M; Novak RM; Rodvold KA
Pharmacotherapy; 2004 May; 24(5):592-9. PubMed ID: 15162893
[TBL] [Abstract][Full Text] [Related]
10. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.
Mitsuyasu RT; Skolnik PR; Cohen SR; Conway B; Gill MJ; Jensen PC; Pulvirenti JJ; Slater LN; Schooley RT; Thompson MA; Torres RA; Tsoukas CM
AIDS; 1998 Jul; 12(11):F103-9. PubMed ID: 9708399
[TBL] [Abstract][Full Text] [Related]
11. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
Cameron DW; Japour AJ; Xu Y; Hsu A; Mellors J; Farthing C; Cohen C; Poretz D; Markowitz M; Follansbee S; Angel JB; McMahon D; Ho D; Devanarayan V; Rode R; Salgo M; Kempf DJ; Granneman R; Leonard JM; Sun E
AIDS; 1999 Feb; 13(2):213-24. PubMed ID: 10202827
[TBL] [Abstract][Full Text] [Related]
12. Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.
López-Cortés LF; Ruiz-Valderas R; Viciana P; Mata R; Gómez-Vera J; Alarcón A; Pachón J
J Acquir Immune Defic Syndr; 2003 Feb; 32(2):240-2. PubMed ID: 12571537
[No Abstract] [Full Text] [Related]
13. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.
Kilby JM; Sfakianos G; Gizzi N; Siemon-Hryczyk P; Ehrensing E; Oo C; Buss N; Saag MS
Antimicrob Agents Chemother; 2000 Oct; 44(10):2672-8. PubMed ID: 10991842
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
[TBL] [Abstract][Full Text] [Related]
16. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).
Ribera E; Azuaje C; Lopez RM; Domingo P; Soriano A; Pou L; Sánchez P; Mallolas J; Sambea MA; Falco V; Ocaña I; Lopez-Colomes JL; Gatell JM; Pahissa A
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):317-23. PubMed ID: 16249706
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P;
Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388
[TBL] [Abstract][Full Text] [Related]
18. MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.
Katlama C; Pellegrin JL; Lacoste D; Aquilina C; Raffi F; Pialoux G; Vittecoq D; Raguin G; Lantz O; Mouroux M; Calvez V; Trylesinski A; Montestruc F; Dohin E; Goehrs JM; Delfraissy JF
HIV Med; 2001 Jan; 2(1):20-6. PubMed ID: 11737372
[TBL] [Abstract][Full Text] [Related]
19. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
Figgitt DP; Plosker GL
Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone].
Tsuchiya K; Hirabayashi Y; Imai K; Kikuchi Y; Tachikawa N; Genka I; Teruya K; Yasuoka A; Oka S; Kimura S
Kansenshogaku Zasshi; 2003 Jun; 77(6):436-42. PubMed ID: 12872693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
